Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M406495200 on August 10, 2004

J. Biol. Chem., Vol. 279, Issue 44, 45312-45321, October 29, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/44/45312    most recent
M406495200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by González-Navarro, H.
Right arrow Articles by Santamarina-Fojo, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by González-Navarro, H.
Right arrow Articles by Santamarina-Fojo, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Ligand-binding Function of Hepatic Lipase Modulates the Development of Atherosclerosis in Transgenic Mice*

Herminia González-Navarro{ddagger}, Zengxuan Nong{ddagger}, Marcelo J. A. Amar{ddagger}, Robert D. Shamburek{ddagger}, Jamila Najib-Fruchart||, Beverly J. Paigen§, H. Bryan Brewer, Jr.{ddagger}, and Silvia Santamarina-Fojo{ddagger}

From the {ddagger}Molecular Disease Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892, the §Jackson Laboratory, Bar Harbor, Maine 04609, and ||Institut Pasteur, Lille 59019, France

Received for publication, June 10, 2004 , and in revised form, August 2, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
To investigate the separate contributions of the lipolytic versus ligand-binding function of hepatic lipase (HL) to plasma lipoprotein metabolism and atherosclerosis, we compared mice expressing catalytically active wild-type HL (HL-WT) and inactive HL (HL-S145G) with no endogenous expression of mouse apoE or HL (E-KO x HL-KO, where KO is knockout). HL-WT and HL-S145G reduced plasma cholesterol (by 40 and 57%, respectively), non-high density lipoprotein cholesterol (by 48 and 61%, respectively), and apoB (by 36 and 44%, respectively) (p < 0.01), but only HL-WT decreased high density lipoprotein cholesterol (by 67%) and apoA-I (by 54%). Compared with E-KO x HL-KO mice, both active and inactive HL lowered the pro-atherogenic lipoproteins by enhancing the catabolism of autologous 125I-apoB very low density/intermediate density lipoprotein (VLDL/IDL) (fractional catabolic rates of 2.87 ± 0.04/day for E-KO x HL-KO, 3.77 ± 0.03/day for E-KO x HL-WT, and 3.63 ± 0.09/day for E-KO x HL-S145G mice) and 125I-apoB-48 low density lipoprotein (LDL) (fractional catabolic rates of 5.67 ± 0.34/day for E-KO x HL-KO, 18.88 ± 1.72/day for E-KO x HL-WT, and 9.01 ± 0.14/day for E-KO x HL-S145G mice). In contrast, the catabolism of apoE-free, 131I-apoB-100 LDL was not increased by either HL-WT or HL-S145G. Infusion of the receptor-associated protein (RAP), which blocks LDL receptor-related protein function, decreased plasma clearance and hepatic uptake of 131I-apoB-48 LDL induced by HL-S145G. Despite their similar effects on lowering pro-atherogenic apoB-containing lipoproteins, HL-WT enhanced atherosclerosis by up to 50%, whereas HL-S145G markedly reduced aortic atherosclerosis by up to 96% (p < 0.02) in both male and female E-KO x HL-KO mice. These data identify a major receptor pathway (LDL receptor-related protein) by which the ligand-binding function of HL alters remnant lipoprotein uptake in vivo and delineate the separate contributions of the lipolytic versus ligand-binding function of HL to plasma lipoprotein size and metabolism, identifying an anti-atherogenic role of the ligand-binding function of HL in vivo.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Hepatic lipase (HL)1 is a 64-kDa lipolytic enzyme that plays a major role in lipoprotein metabolism. It is synthesized and secreted primarily by hepatocytes (1, 2) and is anchored to the vascular endothelium via heparin sulfate proteoglycans. HL functions both as an acylglycerol hydrolase and a phospholipase, hydrolyzing triglycerides (TG) and phospholipids (PL) in chylomicron remnants and intermediate density lipoproteins (IDL). In humans, HL plays a major role in determining low density lipoprotein (LDL) subclass distribution, which may in turn modulate atherogenic risk (3–7). HL is also an important determinant of high density lipoprotein (HDL) concentration and subclass distribution, converting the phospholipid-rich HDL2 to HDL3 (3, 4, 8–14).

In addition to its function as a lipolytic enzyme, HL has a separate role in lipoprotein metabolism by directly facilitating the uptake of lipoproteins and lipoprotein lipids by cell-surface receptors and/or proteoglycans. In this respect, HL could serve as a ligand that facilitates these interactions or, alternatively, could function as a coreceptor. In vitro studies have demonstrated that HL enhances the binding and/or uptake of chylomicrons, chylomicron remnants, {beta}-very low density protein (VLDL), and LDL (15–20) as well as HDL cholesterol (HDL-C) (18, 20–22) in a variety of cell types. Cell-surface receptors, including the LDL receptor (LDLR), low density lipoprotein receptor-related protein (LRP), and SR-BI, as well as cell-surface proteoglycans, have been implicated in this process (15–17, 20, 22). Initial evidence for a ligand-binding function of HL in cellular lipid uptake and lipoprotein metabolism, independent of the lipolytic function of the lipase, came from studies using heat-inactivated HL (18) and anti-HL antibodies (19, 23). These data were confirmed and extended by in vivo experiments that either infused the receptor-associated protein (RAP) and anti-HL/LDLR antibodies (24) or expressed a catalytically inactive form of HL, HL-S145G, in various mouse models. Adenoviral and transgenic overexpression of HL-S145G in apoE knockout (E-KO) mice demonstrated that the ligand-binding function of HL lowers the plasma concentrations of apoB-containing lipoproteins (apoB-Lp) in the absence of apoE (25, 26). Decreased apoB-Lp levels are also observed in transgenic mice that overexpress catalytically inactive HL in LDLR knockout (KO) mice (27). Finally, adenoviral expression of HL-S145G in mice with no endogenous expression of HL (HL-KO) decreased the plasma concentrations of HDL-C by mechanisms independent of lipolysis (28). However, these in vivo reports are limited by the confounding effects of having fully active, endogenous mouse HL present along with HL-S145G in the adenovirus and transgenic studies in E-KO mice and by non-steady-state expression of catalytically inactive HL-S145G in the adenovirus studies (25, 26, 28). More recently, Dichek et al. (29) reported that overexpression of catalytically inactive HL in LDLR-KO, LDLR-KO x apoB-100, and LDLR-KO x apoB-48 (HL-KO) mice facilitates the clearance of apoB-48- and apoB-100-containing lipoproteins. Recent studies in human patients with HL deficiency also support an important role of the ligand-binding function of HL in vivo. Zambon et al. (30) showed that the presence or absence of HL protein in HL-deficient subjects leads to significant differences in the cholesterol content of apoB-Lp. These combined data support an important physiological role for the ligand-binding function of HL in lipoprotein metabolism in vivo.

These multiple functions of HL, which facilitate not only plasma lipid metabolism, but also cellular lipid uptake, can be anticipated to have a major and complex impact on atherogenesis. Indeed, human and animal studies support both pro-atherogenic and anti-atherogenic roles for HL (14, 31–33). In humans, low or absent HL activity has been associated with increased risk of coronary artery disease (31, 34, 35). Other studies have concluded that decreased HL activity does not influence susceptibility to coronary artery disease (8). Finally, increased HL activity has been reported in patients with coronary artery disease (36, 37). A pro-atherogenic role for HL has been suggested from the inverse correlation between increased HL activity and the plasma levels of anti-atherogenic HDL and the positive correlation with small, dense, pro-atherogenic LDL (37, 38).

Analyses of transgenic and knockout animal models have also provided conflicting data regarding the role that HL plays in atherosclerosis. HL overexpression beneficially alters the plasma lipid profile of mice and rabbits by reducing the amount of cholesterol present in apoB-Lp (26, 27, 39). In addition, overexpression of human HL reduces the aortic cholesterol content in cholesterol-fed mice (40). However, in both species, HL also leads to the formation of potentially small, dense, pro-atherogenic LDL (41–43). Finally, HL deficiency in E-KO and lecithin:cholesterol acyltransferase-overexpressing transgenic mice significantly reduces aortic atherosclerosis despite the increase in cholesterol content in apoB-Lp (44, 45). These conflicting data in mice have been explained in part by the recent discovery of HL expression in mouse macrophages (46) and by bone marrow transplantation studies demonstrating that macrophage HL expression in the arterial wall enhances early lesion formation in E-KO and lecithin:cholesterol acyltransferase-overexpressing transgenic mice, without modification of plasma lipoprotein lipids or HL activities (45). Despite these recent advances, the independent roles of the ligand-binding versus lipolytic function in lipoprotein metabolism and the development of atherosclerosis are not well defined.

Here, we have investigated the effects of the lipolytic versus the ligand-binding function of HL on plasma lipoprotein metabolism and atherosclerosis. In this study, we utilized mice with stable, steady-state expression of catalytically active HL-WT or inactive HL-S145G in liver in a background lacking endogenous HL or apoE to circumvent the limitations encountered in previous studies. We demonstrate that whereas the lipolytic function of HL significantly contributes to plasma HDL metabolism, the ligand-binding function of HL is responsible for lowering the plasma concentrations of pro-atherogenic apoB-Lp by enhancing their catabolism via the LRP pathway. Despite their similar effects on lowering pro-atherogenic apoB-Lp, expression of HL-WT enhances atherosclerosis, whereas expression of HL-S145G markedly reduces aortic atherosclerosis in E-KO mice. These data define a major receptor pathway by which the ligand-binding function of HL alters apoB-Lp catabolism in vivo and identify divergent roles for the lipolytic versus ligand-binding function of HL in lipoprotein metabolism and atherosclerosis.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Mice and Diets—The generation of pCMV vectors containing wild-type and catalytically inactive human HL cDNAs has been described previously (25, 28). A 1.6-kb fragment of human HL cDNA was excised from the pCMV vector and subcloned into the expression plasmid pLIV.11 (39) modified by the addition of NotI linkers. After digestion with SalI and SpeI, a fragment containing the human apoE promoter, the human HL cDNA, the poly(A) signal from the human apoE gene, and the hepatic and macrophage control regions of the apoE/apoC-I locus was isolated and injected into the male pronucleus of fertilized eggs from superovulating C57BL/6N females (Charles River Laboratories, Wilmington, MA). Integration of the human HL cDNA in newborn mice was determined by dot blot and Southern blot hybridization of genomic tail DNA using the full-length human HL cDNA as a probe. Human HL transgenic mice were crossbred with HL-KO (47) and E-KO (48) mice with a C57BL/6J background to generate HL transgenic mice homozygous for both mouse HL and apoE deficiency. Animals were fed a rodent autoclaved chow diet (NIH-07 chow diet, 0.025% cholesterol and 4.5% fat; Ziegler Brothers, Inc., Gardner, PA).

Northern and Western Blot Analyses—Total mouse RNA was isolated from mouse liver, spleen, heart, lung, fat, ovary, brain, kidney, and macrophages using TRIzol (Invitrogen, Carlsbad, CA), and human liver poly(A)+ RNA was purchased from Ambion Inc. (Austin, TX). Northern blot analysis was performed as described (46). The membrane was hybridized with a digoxigenin-labeled human or mouse HL riboprobe and detected using a digoxigenin chemiluminescent detection kit (Roche Applied Science, Indianapolis, IN). The human HL riboprobe was generated by transcription of a 554-bp SmaI-EcoRV fragment of human HL cDNA and subcloned into pBluescript II (Stratagene, La Jolla, CA). The mouse riboprobe was generated by transcription of a 462-bp ApaI-EcoRI fragment of mouse HL cDNA subcloned into pBluescript II. A 32P-labeled 693-bp cyclophilin cDNA probe (Ambion Inc.) was used for standardization. For protein expression studies, HL protein was isolated from pre- or post-heparin plasma using a HiTrap heparin column (Amersham Biosciences, Uppsala, Sweden), and liver homogenates were prepared from 100 mg of tissue as described (46). Post-heparin plasma HL and liver receptors were analyzed by electrophoresis followed by immunoblotting using an Immobilon membrane (Millipore, Bedford, MA); probed with rat anti-HL antibody (1 µg/ml) (49), human anti-HL antibody (1 µg/ml) (50), or commercial mouse anti-LRP monoclonal (1 µg/ml) or rabbit anti-LDLR polyclonal (1 µg/ml) antibody (Research Diagnostics, Inc., Flanders, NJ), and detected by chemiluminescence (Supersignal WestPico kit, Pierce, Rockford, IL) using horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) (46). The human and mouse riboprobes were highly specific for each species.

Post-heparin Plasma HL and Lipoprotein Lipase Activities—Post-heparin plasma was obtained 5 min after bolus infusion of heparin (500 units/kg; American Pharmaceutical Partners Inc., Schaumburg, IL) into the mouse tail vein and stored frozen at –80 °C. HL and lipoprotein lipase activities were assayed by incubation with radiolabeled triolein (Amersham Biosciences, Piscataway, NJ) in the presence or absence of 1 M NaCl as described (51).

Analysis of Plasma, Lipid Lipoproteins, and Apolipoproteins—After a 4-h fast, mouse plasma samples were collected from blood obtained from the retro-orbital plexus of mice anesthetized with methoxyflurane (Pitman-Moore, Mundelein, IL) and placed into precooled tubes containing EDTA as reported (45). Total cholesterol (TC), TG, PL, and free cholesterol (FC) in plasma samples were analyzed using enzyme kits (Sigma, St. Louis, MO) as described (45). HDL-C was determined as the cholesterol remaining after precipitation of apoB-Lp with dextran sulfate (Bayer Corp., Tarrytown, NY) as described (28). Non-HDL-C was obtained by subtraction of the HDL-C from the TC. Plasma apolipoprotein levels from four to six control and transgenic mice were analyzed by sandwich enzyme-linked immunosorbent assay using polyclonal antibodies against synthetic peptides of mouse apoA-I and apoB as described (45) and by 4–12% SDS-PAGE (0.2–1 µl of plasma). Separated plasma lipoproteins were transferred to an Immobilon membrane. The blots were probed with monospecific mouse anti-apoA-I, anti-apoA-II, anti-apoB, and anti-apoE antibodies (BIODESIGN International, Kennebunkport, ME), and signal was detected by chemiluminescence reaction (Supersignal WestPico kit) using horseradish peroxidase-conjugated secondary antibody (46) and quantitated by densitometry (Amersham Biosciences personal densitometer). The mouse anti-apoB antibody reacted with both mouse apoB-48 and apoB-100.

For FPLC plasma lipoprotein analysis, 100 µl of pooled mouse plasma (n = 5) were separated by gel filtration using two Superose 6 HR 10/30 columns (Amersham Biosciences) connected in series (45). Lipids in the recovered fractions were analyzed using enzyme kits as described (25, 28). The elution volumes of the plasma lipoproteins separated by FPLC were as follows: VLDL, 15.0–17.0 ml; IDL/LDL, 19.0–23.0 ml; and HDL, 29.0–31.0 ml. For native agarose gel electrophoresis, 2 µl of total plasma from three to four control and transgenic mice each were loaded onto a Titan gel (Helena Laboratories, Beaumont, TX) and electrophoresed for 40 min at 60 V. The content of cholesterol was quantified by staining with fat red B (Helena Laboratories).

Lipoprotein Particle Lipid Composition and Size Analysis—Lipoproteins were isolated from 2.5 ml of mouse plasma by sequential ultra-centrifugation in KBr solutions at 100,000 rpm for 5 h at 5 °C (mouse VLDL/IDL, d < 1.019 g/ml; mouse LDL, d = 1.019–1.063 g/ml; mouse HDL, d = 1.063–1.21 g/ml; and human LDL, d = 1.050–1.030 g/ml) using a TLA-100.2 rotor in a TL-100 ultracentrifuge (Beckman Instruments, Palo Alto, CA). After centrifugation, samples were extensively dialyzed against phosphate-buffered saline, and their lipid and apolipoprotein content was measured as described above. To determine lipoprotein particle size, VLDL/IDL, LDL, and HDL fractions from each mouse group were analyzed by nondenaturing polyacrylamide gradient gel electrophoresis (52). VLDL/IDL and LDL were electrophoresed at 35 V for 17 h at 4 °C using Tris/glycine-polyacrylamide (4–12%) gradient gels (Invitrogen). HDL fractions were separated by electrophoresis at 90 V for 90 min using Tris borate-polyacrylamide (3–30%) gradient gels (Gradipore, Buffalo Grove, IL). Gels were fixed and stained either with 0.04% oil red O in 60% ethanol for lipids or with 0.1% Coomassie Brilliant Blue R-250, 50% methanol, and 9% acetic acid for proteins, and then they were scanned with a densitometer FluorChemTM 8800 imaging system (Alpha Innotech, Imgen Technologies, Alexandria, VA). The migration distance for each particle was obtained from the densitometer, and the molecular diameter was calculated from a calibration curve generated from the migration distances of size standards of known diameter, including polystyrene carboxylate-modified beads (400 Å) (Duke Scientific Corp., Palo Alto, CA) and thyroglobulin (170 Å), ferritin (122 Å), catalase (104 Å), lactate dehydrogenase (81 Å), and bovine serum albumin (71 Å) (Amersham Biosciences), and lipoprotein standards of known molecular diameter.

Metabolic Studies—Lipoproteins were isolated from 2.5 ml of mouse or 50 ml of human plasma by sequential ultracentrifugation in KBr solutions. Mouse 131I-labeled apoB VLDL/IDL and 125I-labeled apoB LDL and human 131I-labeled apoB LDL were prepared by a modification of the iodine monochloride method (53). VLDL/IDL and LDL (1–1.2 mg each) were labeled with 125I or 131I at an efficiency of 29–37%. Mouse 131I-labeled apoB VLDL/IDL and 125I-labeled apoB LDL and human 131I-labeled apoB LDL were then re-isolated by ultracentrifugation and dialyzed overnight against 1x phosphate-buffered saline and 0.01% EDTA. Radiolabeled lipoproteins were analyzed by FPLC and agarose gel electrophoresis to ensure the integrity of the particles. Mouse 131I-labeled apoB VLDL/IDL (1 x 106 dpm) and 125I-labeled apoB LDL (1 x 106 dpm) and human 131I-labeled apoB LDL (1 x 106 dpm) were injected into the saphenous veins of the three different mouse groups (n = 6 per group). Mice were bled at different time points, and 125I-labeled apoB and 131I-labeled apoB radioactivity were analyzed. For quantification of human 131I-labeled apoB remaining in plasma in the human LDL study, the total plasma was analyzed for its radioactivity content. In mouse VLDL/IDL and LDL studies, 2–5 µl of mouse plasma were fractionated by SDS-PAGE using 4–12% gradient gels; the apoB bands were excised; and 125I-labeled apoB was quantified using a {gamma}-counter (Cobra Autogama, Packard Instruments Co.) (25). The fractional catabolic rate (FCR) was determined from the area under the apoB radioactivity curves using a multi-exponential curve fitting technique in the WinSAAM program (Version 3.0.1) (54).

RAP Studies—We first determined the minimal concentration of RAP required for partial in vivo LRP inhibition by measuring the uptake of the LRP ligand {alpha}2-macroglobulin (Research Diagnostics, Inc.) after injection of RAP protein (Research Diagnostics, Inc.). {alpha}2-Macroglobulin was activated with 200 mM methylamine for 1 h at room temperature, 125I-radiolabeled as described (55, 56), and injected (3–5 µg, 10 x 106 dpm/30 g of body weight) 1 min after a bolus infusion of 0.3 mg of RAP/30 g of body weight. This RAP dose, which resulted in 36% inhibition of 125I-labeled {alpha}2-macroglobulin liver uptake in RAP-injected (n = 3) versus saline-injected (n = 3) mice, was then used for the actual studies. Mouse 125I-apoB-48 LDL (30 x 106 dpm/30 g of body weight), isolated as described above from E-KO x HL-KO mice, was injected into HL-S145G mice 1 min after either RAP or saline injection. Blood samples were obtained at 1, 5, 10, 20, and 30 min. After flushing, the liver was removed and weighed, and a small portion was removed for assay for 125I at 30 min. Radioactivity remaining in plasma 125I-apoB-48 LDL was determined as described above.

Analysis of Aortic Lesions—The heart and the attached section of the ascending aorta were prepared and analyzed as described (45). The proximal aorta was collected after saline perfusion, and the aorta was placed in 4% phosphate-buffered formaldehyde solution for 24 h and then transferred to 10% phosphate-buffered formaldehyde solution for 5 days. Specimens were embedded in 25% gelatin and sectioned with a cryostat at –25 °C. The aortic root and ascending aorta were sectioned at a thickness of 10 mm, and alternate sections were saved on slides and stained with oil red O for neutral lipids and hematoxylin. Five sections/animal were evaluated for the cross-sectional area of lesions from the aortic root for a distance of 350 mm at 80-mm intervals as reported previously (57).

Statistical Analysis—Data are presented as the means ± S.E. Unpaired Student's t test was performed for analysis of the plasma lipid concentrations and lipase activities. Non-parametric data were analyzed using the Mann-Whitney test (Instat software, GraphPad, Inc., San Diego, CA).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Expression of Human HL in E-KO x HL-KO Mice—Northern blot hybridization of total liver RNA using the HL riboprobe demonstrated expression of the 1.6-kb HL-WT and mutant HL-S145G mRNAs in the liver (Fig. 1A) but not in spleen, heart, lung, fat, ovary, brain, kidney, and macrophages (data not shown) of E-KO x HL-WT and E-KO x HL-S145G transgenic mice. The absence of mouse HL mRNA was verified by Northern blot analysis using a mouse-specific HL riboprobe (data not shown). Following partial purification by heparin-Sepharose affinity chromatography, immunoblot analysis using a monospecific anti-HL monoclonal antibody identified the 64-kDa HL-WT and mutant HL-S145G protein bands in post-heparin plasma of E-KO x HL-WT and E-KO x HL-S145G transgenic mice and normal human controls, but not in that of E-KO x HL-KO mice (Fig. 1B). Densitometric scans of Northern (Fig. 1A) and Western (Fig. 1B) blots revealed that compared with human samples, HL expression in liver and post-heparin plasma was increased by ~3–5-fold in E-KO x HL-WT and E-KO x HL-S145G transgenic mice (data not shown). Post-heparin HL activity was present in E-KO x HL-WT mice (325 ± 34 nmol/min/ml), but was undetectable in E-KO x HL-KO and E-KO x HL-S145G transgenic mice (<20 nmol/min/ml), confirming the lack of functional activity of the human HL-S145G enzyme. Analysis of post-heparin plasma revealed that lipoprotein lipase activity was decreased by ~23% (p < 0.003) in both E-KO x HL-WT (940 ± 45 nmol/min/ml) and E-KO x HL-S145G (929 ± 54 nmol/min/ml) mice compared with E-KO x HL-KO mice (1223 ± 56 nmol/min/ml).



View larger version (43K):
[in this window]
[in a new window]
  		FIG. 1.
Expression of HL-WT and HL-S145G in mice. A, Northern analysis of total RNA from E-KO x HL-KO (15 µg), E-KO x HL-WT (15 µg), or E-KO x HL-S145G (15 µg) mouse liver hybridized with HL (upper panel) or cyclophilin (lower panel) riboprobes. B, Western analysis of partially purified HL (1 µg) isolated from human or E-KO x HL-KO, E-KO x HL-WT, and E-KO x HL-S145G mouse post-heparin plasma. hHL STD, human HL standard.

 
Catalytically Active HL-WT and Inactive HL-S145G Lower the Plasma Concentrations of ApoB-Lp in E-KO x HL-KO Mice—Previous studies have shown that HL deficiency significantly raises the plasma TC, non-HDL-C, and apoB levels in E-KO mice (44, 45, 58). Consistently, compared with male and female E-KO x HL-KO mice, male and female E-KO x HL-WT mice that expressed fully active HL had reduced plasma levels of TC (by 40% (p < 0.01) and 42% (p < 0.0001), respectively), TG (by 27% (p = 0.04) and 52% (p < 0.0001), respectively), PL (by 43 and 50% (p < 0.0002), respectively), cholesterol ester (CE; by 47% (p < 0.002) and 45% (p < 0.0001), respectively), HDL-C (by 67% (p < 0.0001) and 40% (p < 0.02), respectively), non-HDL-C (by 48% (p < 0.002) and 44% (p < 0.0001), respectively), apoB (by 36 and 35% (p < 0.0001), respectively), and apoA-I (by 54 and 46% (p < 0.0001), respectively) (Fig. 2A). Most of the reduction in plasma TC was due to decreased VLDL cholesterol (Fig. 2B). Similarly, increased expression of catalytically inactive HL-S145G in male and female E-KO x HL-KO mice (Fig. 2A) markedly decreased the plasma levels of TC (by 57 and 52% (p < 0.0001), respectively), TG (by 26% (p = 0.05) and 42% (p < 0.0001), respectively), PL (by 39 and 43% (p < 0.0001), respectively), CE (by 57 and 52% (p < 0.0001), respectively), non-HDL-C (by 61 and 55% (p < 0.0001), respectively), and apoB (by 44 and 45% (p < 0.0001), respectively). In contrast to HL-WT, catalytically inactive HL-S145G did not significantly alter plasma HDL-C or apoA-I levels in E-KO x HL-KO mice (Fig. 2A). As in E-KO mice expressing HL-WT, analysis of plasma lipoproteins in E-KO x HL-S145G mice by FPLC (Fig. 2B) and native agarose gel electrophoresis (data not shown) revealed that most of the cholesterol reduction occurred in pro-atherogenic apoB-Lp, especially VLDL.



View larger version (41K):
[in this window]
[in a new window]
  		FIG. 2.
Plasma lipid, lipoprotein, and apolipoprotein analysis. A, plasma lipids, lipoproteins and apolipoproteins of female (upper panel) and male (lower panel) E-KO x HL-KO (black bars), E-KO x HL-WT (white bars), and E-KO x HL-S145G (gray bars) mice. B, FPLC cholesterol profiles of pooled plasma from female (upper panel) and male (lower panel) E-KO x HL-KO ({square}; n = 5), E-KO x HL-WT ({blacktriangleup}; n = 5), and E-KO x HL-S145G ( n = 5) mice. Immunoblots of apoB-100, apoB-48, and apoA-I present in FPLC fractions are shown in the inset. Data are expressed as the means ± S.E. {dagger}, p < 0.05; {dagger}{dagger}, p < 0.02; *, p < 0.0002 (compared with E-KO x HL-KO mice).

 
Direct comparison of the plasma lipid profiles of E-KO x HL-WT and E-KO x HL-S145G mice revealed small differences in plasma TG and PL concentrations, but major differences in plasma HDL-C and apoA-I concentrations; male E-KO mice expressing lipolytically active HL-WT had lower plasma TG (by 18%, p = 0.05), PL (by 22%, p = 0.01), HDL-C (by 73%, p < 0.0001), and apoA-I (by 56%, p < 0.00001) levels (p < 0.01, all) than male E-KO x HL-S145G mice (Fig. 2A). Similarly, female E-KO mice expressing lipolytically active HL-WT had lower plasma TG (by 16%, p < 0.05), PL (by 17%, p < 0.05), HDL-C (by 44%, p < 0.0001), and apoA-I (by 52%, p < 0.00001) levels (p < 0.03, all) than female E-KO x HL-S145G mice (Fig. 2A). The marked decrease in plasma lipid and lipoprotein levels in mice expressing only catalytically inactive HL-S145G demonstrates that the ligand-binding function of HL plays a major role in reducing the plasma levels of apoB-Lp in the E-KO mouse model. In contrast, the lipolytic function of HL appears to be necessary for the effect of HL on HDL-C in this mouse model.

Catalytically Active HL-WT and Inactive HL-S145G Differentially Alter Lipoprotein Particle Lipid Content and Size—HL can significantly alter not only the plasma levels but also the composition of different plasma lipoproteins (7–9, 11–16, 19, 23, 24, 27, 28, 31, 41, 42). However, to date, the separate contributions of the lipolytic versus ligand-binding functions of HL to VLDL, IDL, LDL, and HDL lipid content and particle size have not been investigated. In this study, we isolated VLDL/IDL (d < 1.019), LDL (d = 1.019–1.063), and HDL (d = 1.063–1.21) by sequential density ultracentrifugation from each study mouse group and determined the lipid and apolipoprotein concentrations (Table I) as well as lipoprotein particle size (Fig. 3) in each density fraction.


View this table:
[in this window]
[in a new window]
  		TABLE I
Lipoprotein lipid concentrations in E-KO x HL-KO, E-KO x HL-WT, and E-KO x HL-S145G mice

The lipid and apolipoprotein concentrations of VLDL/IDL (d < 1.019), LDL (d = 1.019–1.063), and HDL (d = 1.063–1.21) fractions isolated by sequential ultracentrifugation from pooled (n = 20 each group) E-KO x HL-KO, E-KO x HL-WT, and E-KO x HL-S145G mouse plasma are shown. Data shown are the means of at least two experiments.

 



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 3.
Densitometric tracings of protein-stained polyacrylamide gradient gels after electrophoresis of isolated lipoproteins. Shown are the results from analysis of VLDL/IDL (d < 1.019) and LDL (d = 1.019–1.063) fractions by native 4–12% gradient gel electrophoresis (A and B) and HDL fractions (d = 1.063–1.21) (C) by native 3–30% gradient gel electrophoresis isolated from E-KO x HL-KO, E-KO x HL-WT, and E-KO x HL-S145G mice. The diameters (in Å) of the major lipoprotein species are indicated.

 
As expected, from the combined effects of both the lipolytic and ligand-binding functions of HL present in mice expressing HL-WT, the TC, CE, FC, TG, and PL as well as apoB concentrations were decreased in the VLDL/IDL density fractions isolated from E-KO x HL-WT mice compared with E-KO x HL-KO mice (Table I). Most of the reduction in the total plasma lipids of E-KO x HL-WT mice reflected changes in the lipid concentration of the VLDL/IDL fraction; however, HL-WT also decreased the TC, CE, FC, TG, PL, and apoB concentrations in LDL density fractions and the TC, CE, FC, TG, PL, and apoA-I concentrations in HDL density fractions isolated from E-KO x HL-WT mice compared with E-KO x HL-KO mice (Table I).

To determine which of the changes in the lipid content of the lipoprotein fractions was due to the ligand-binding functions of HL, a similar analysis was performed for particles isolated from E-KO x HL-KO mice expressing catalytically inactive HL-S145G. Compared with E-KO x HL-KO mice, HL-S145G also reduced the concentrations of TC, CE, FC, TG, PL, and apoB in the VLDL/IDL density fractions from E-KO x HL-S145G mice (Table I). These findings, including the decrease in VLDL/IDL PL and TG concentrations, are consistent with the function of HL-S145G as a ligand that facilitates the cellular uptake of these lipoprotein particles. In contrast to VLDL/IDL, catalytically inactive HL-S145G had virtually no effect on the concentrations of TC, CE, FC, TG, PL, and apoB in LDL density fractions isolated from E-KO x HL-S145G mice compared with E-KO x HL-KO mice; however, the fraction of plasma TC present in LDL was 2-fold greater in E-KO x HL-S145G mice compared with E-KO x HL-KO mice. Virtually no differences in the concentrations of TC, CE, FC, TG, PL, and apoA-I in the HDL density fractions were evident between E-KO x HL-S145G and E-KO x HL-KO mice.

Direct comparison of the lipid and apolipoprotein concentrations of the various lipoprotein density fractions isolated from mice expressing HL-WT versus HL-S145G (Table I) revealed that except for TG, all lipid (including TC, CE, FC, and PL) and apoB concentrations were lower in VLDL/IDL fractions isolated from E-KO x HL-S145G mice. In contrast, TC, CE, FC, PL, and TG concentrations were higher in both the LDL and HDL fractions isolated from E-KO x HL-S145G mice compared with E-KO x HL-WT mice. Thus, the metabolic impact of the lipolytic function of HL is greater than that of the ligand-binding function of HL on both LDL and HDL.

The changes in lipoprotein lipid and apolipoprotein content resulting from expression of HL-WT and HL-S145G (Table I) are anticipated to alter lipoprotein particle size. Thus, the sizes of VLDL/IDL, LDL, and HDL isolated from E-KO x HL-KO, E-KO x HL-WT, and E-KO x HL-S145G mice were analyzed by native polyacrylamide gel electrophoresis (Fig. 3, A–C). The major lipoprotein particles in the VLDL/IDL fraction isolated from E-KO x HL-KO mice were >400, 369, and 348 Å (Fig. 3A). The marked reduction in the 369- and 348-Å particles in the VLDL/IDL fractions isolated from both E-KO x HL-WT and E-KO x HL-S145G mice (Fig. 3A) indicates that the ligand-binding rather than lipolytic function of HL may be responsible for the clearance of the lipoprotein particles within VLDL/IDL. In contrast, the lipolytic versus ligand-binding function of HL had differential effects on both LDL and HDL. Fig. 3B demonstrates that the complete absence of HL (E-KO x HL-KO mice) led to the accumulation of mainly 259- and 254-Å LDL particles (Fig. 3B, upper panel). Expression of HL-S145G, which has only ligand-binding activity, resulted in the accumulation of lipoprotein particles with a broad size distribution (ranging from 320 to 254 Å) in the LDL fraction, whereas HL-WT expression, which restores lipolytic activity, dramatically reduced the size and heterogeneity of particles in the LDL fraction (259 and 254 Å) (Fig. 3, B and C). Similarly, a major difference in HDL particle size was observed in mice expressing the active HL-WT enzyme versus the inactive HL-S145G enzyme. HDL size (Fig. 3C) and lipid content (Table I) were similar in the E-KO x HL-KO and E-KO x HL-S145G mice, indicating a minimal effect of the ligand function of HL; however, both were markedly decreased in E-KO x HL-WT mice, consistent with the known role of HL-mediated lipolysis in remodeling HDL (Fig. 3C).

Catalytically Inactive HL-S145G Alters the Plasma Lipid Profile by Enhancing the Catabolism of ApoB-48-containing Lipoproteins in E-KO x HL-KO Mice—We next investigated the in vivo mechanism by which the ligand-binding function of HL alters the metabolism of pro-atherogenic apoB-Lp in E-KO x HL-KO mice. To address this question under steady-state conditions and without the confounding effects of endogenous mouse HL, we performed kinetic studies in E-KO mice with no endogenous expression of mouse HL and stable, long-term expression of catalytically inactive HL-S145G. As most of the cholesterol present in apoB-Lp in E-KO x HL-KO, E-KO x HL-WT, and E-KO x HL-S145G mice accumulates in VLDL/IDL, we first studied the metabolism of VLDL/IDL in these mice by injection of autologous 131I-labeled apoB-48 VLDL (Fig. 4A, inset) into E-KO x HL-KO, E-KO x HL-WT, and E-KO x HL-S145G mice. As shown in Fig. 4A, HL-WT and HL-S145G markedly enhanced the catabolism of 131I-labeled apoB-48 VLDL/IDL (FCR = 3.63 ± 0.09/day and 3.77 ± 0.33/day, respectively; p < 0.02) in E-KO x HL-KO control mice (FCR = 2.87 ± 0.04/day). Interestingly, VLDL/IDL FCR were similar between mice expressing HL-WT and HL-S145G, indicating that the ligand-binding and not the lipolytic function of HL is primarily responsible for enhancing VLDL/IDL catabolism. Both HL-WT and HL-S145G increased the catabolism of 125I-labeled apoB-48 LDL (FCR = 18.88 ± 1.72/day and 9.01 ± 0.14/day, respectively; p < 0.001) in E-KO x HL-KO control mice (FCR = 5.67 ± 0.34/day) (Fig. 3B). However, expression of fully active HL-WT further enhanced (by ~2-fold) the clearance of apoB-48 LDL compared with expression of HL-S145G. The differences observed in mouse apoB-48 LDL catabolism were not due to variable expression of the LDLR, as Western blot analysis revealed that hepatic LDLR levels were similar in E-KO x HL-WT and E-KO x HL-S145G mice (Fig. 4C, inset). However, LDLR gene expression was lower in E-KO x HL-KO mice than in E-KO mice expressing HL-WT or HL-S145G (Fig. 4C, inset). These studies demonstrate that, in the absence of apoE, catalytically inactive HL-S145G is able to facilitate the catabolism of apoB-48 VLDL/IDL and LDL in vivo; however, effective clearance of LDL requires the lipolytic function of HL.



View larger version (27K):
[in this window]
[in a new window]
  		FIG. 4.
In vivo metabolism of apoB-Lp in mice expressing HL-WT and HL-S145G. Shown is the catabolism of mouse autologous 131I-labeled apoB VLDL/IDL (A), mouse autologous 125I-apoB LDL (B), and human 131I-apoB LDL (C) in E-KO x HL-KO ({square}; n = 6 per group), E-KO x HL-WT ({blacktriangleup}; n = 6 per group), and E-KO x HL-S145G (; n = 6 per group) mice. The apoB-100, apoB-48, and apoE content of the radiolabeled injected particles and the hepatic levels of the LDLR in each mouse group were analyzed by Western blotting (insets). FCR (per day (d–1)) are shown. *, p < 0.05 (compared with E-KO x HL-KO mice).

 
We also studied the plasma kinetics of human 131I-labeled apoB-100 LDL, which lacks both apoE and apoB-48 (Fig. 4C, inset), in all three mouse models. These particles are expected to be cleared primarily by the LDLR. In contrast to mouse apoB-48 VLDL/IDL and LDL, neither HL-WT nor HL-S145G enhanced the catabolism of human 131I-labeled apoB-100 LDL in E-KO x HL-KO mice (FCR = 3.43 ± 0.08/day, 3.94 ± 0.12/day, and 3.69 ± 0.23/day, respectively; p > 0.05) (Fig. 4C).

RAP Infusion Delays the Clearance of LDL Facilitated by HL-S145G—To further investigate the receptor pathways by which the ligand-binding function of HL facilitates the clearance of apoB-48-containing lipoproteins, we studied the in vivo effects of injecting the LRP inhibitor RAP into mice expressing catalytically inactive HL-S145G. Previous studies have shown inhibition of LRP function, as determined by uptake of 125I-labeled {alpha}2-macroglobulin, after infusion of 1–2 mg of RAP/mouse (55, 59). In our studies, we achieved 21.5 ± 4.6% reduction in the plasma clearance of 125I-labeled {alpha}2-macroglobulin and 36% inhibition of 125I-labeled {alpha}2-macroglobulin uptake by liver LRP after bolus infusion of 0.3 mg of RAP/30 g of body weight (p < 0.05). As indicated previously (59), the amount of RAP required to inhibit the LDLR is an order of magnitude greater than that required to inhibit LRP. Since 0.3 mg of RAP achieved only 36% inhibition of LRP, this dose is not likely to inhibit the LDLR. Compared with saline-injected control mice, RAP infusion significantly decreased the plasma clearance of 125I-apoB-48 LDL (expressed as percent remaining 125I-apoB-48 plasma counts) at 5 min (87 ± 1.2 versus 96 ± 1.8, p < 0.02), 10 min (80 ± 1.3 versus 89 ± 2.7, p < 0.03), 20 min (70 ± 0.5 versus 80 ± 1.7, p < 0.006), and 30 min (58 ± 1.8 versus 69 ± 0.8, p < 0.02) after 125I-apoB-48 LDL infusion. In addition, the hepatic uptake of 125I-apoB-48 LDL at 30 min after lipoprotein injection (expressed as percent 125I-apoB-48 liver counts/total liver weight (125I-apoB-48 counts/total liver weight + total plasma counts)) was decreased by ~36% (p < 0.05) in HL-S145G mice infused with RAP (9.5 ± 0.35%) versus saline (15 ± 0.71%). These findings implicate LRP in the catabolism and uptake of apoB-48 LDL from plasma, facilitated by the ligand-binding function of HL.

HL-S145G Significantly Reduces Proximal Aortic Atherosclerosis in E-KO Mice—To investigate the role of catalytically inactive HL-S145G in modulating atherosclerosis, the proximal aortas of male and female E-KO x HL-KO, E-KO x HL-WT, and E-KO x HL-S145G transgenic mice on a regular chow diet (RCD) at 3, 5, and 7 months of age were analyzed (Fig. 5). Consistent with previous reports showing a dissociation between the plasma levels of pro-atherogenic apoB-Lp and development of aortic atherosclerosis in E-KO x HL-KO mice (44, 45), aortic atherosclerosis was significantly increased in female E-KO x HL-WT mice at 3 (3.5-fold, p < 0.001), 5 (9.2-fold, p < 0.0001), and 7 (2.5-fold, p < 0.0001) months of age. A trend toward an increased mean aortic lesion area was noted in male E-KO x HL-WT mice at 3 and 5 months of age, which reached statistical significance at 7 months of age (2-fold, p < 0.04) compared with male E-KO x HL-KO mice. In contrast, the mean aortic lesion area was decreased by 78% (p < 0.0001), 84% (p < 0.001), and 78% (p < 0.0001) in female E-KO x HL-S145G mice at 3, 5, and 7 months of age, respectively. Similarly, lesion development was reduced by 74% (p < 0.02), 96% (p < 0.004), and 76% (p < 0.01) in male E-KO x HL-S145G mice at 3, 5, and 7 months of age compared with their respective E-KO x HL-KO control mice.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 5.
Analysis of proximal aortic atherosclerosis. Mean aortic lesion area was measured in female E-KO x HL-KO ({square}), E-KO x HL-WT ({blacktriangleup}), and E-KO x HL-S145G () mice (left panels) on an RCD at 3 (n = 10, 20, and 17, respectively) (A), 5 (n = 8, 8, and 8, respectively) (B), and 7 (n = 11, 6, and 16, respectively) (C) months of age and in male E-KO x HL-KO ({square}), E-KO x HL-WT ({blacktriangleup}), and E-KO x HL-S145G () mice (right panels) on an RCD at 3 (n = 11, 17, and 11, respectively) (A), 5 (n = 7, 8, and 10, respectively) (B), and 7 (n = 6, 15, and 10, respectively) (C) months of age. {dagger}, p < 0.02; {dagger}{dagger}, p < 0.004; *, p < 0.0001 (E-KO x HL-WT and E-KO x HL-S145G mice compared with E-KO x HL-KO mice). Atherosclerosis was also significantly reduced (p < 0.004) in E-KO x HL-S145G mice compared with E-KO x HL-WT mice.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
HL is a multifunctional protein with ligand-binding and lipolytic activities that significantly alter cellular lipid uptake and lipoprotein metabolism. Data from human (8, 14, 31–34, 36–38) and animal (40, 44, 45) studies indicate that the multiple functions of HL can lead to variable and sometimes opposing effects on lesion development, resulting in unpredictable changes in atherosclerosis. To date, the specific contribution of the ligand-binding function of HL to these various processes and especially to atherosclerosis has not been elucidated.

In this study, we have dissected the effects of the lipolytic versus ligand-binding function of HL on plasma lipoprotein metabolism and atherosclerosis using mice with stable, steady-state expression of catalytically active HL-WT or inactive HL-S145G in liver in a background lacking endogenous HL or apoE. We expressed catalytically active HL-WT and inactive HL-S145G primarily in liver since human HL mRNA was not detected in other tissues, including adrenal glands, ovaries, macrophages, and adipose tissue. Thus, any changes in plasma lipoproteins or atherosclerosis observed in the study transgenic mice are a result of increased liver HL transgene expression. The levels of HL overexpression (3–5-fold) achieved in our transgenic mice were within the physiological range reported previously for various metabolic states such as sex, dietary status, diabetes, and hormonal stimulation (6, 10). This contrasts with previous studies in which HL-WT and catalytically inactive HL were overexpressed by either 10-fold (25) or 20-fold (26) in E-KO mice expressing endogenous HL. Thus, the transgenic mice used in this study express HL in liver at physiologically relevant levels compared with mice lacking endogenous HL.

The lipolytic and ligand-binding functions of HL had differential effects on the plasma lipid profile of E-KO x HL-KO mice. HL-WT markedly lowered the plasma concentrations of TC, TG, PL, CE, non-HDL-C, and apoB by up to 52% (p < 0.01) in E-KO mice, indicating that HL will partially but not completely correct the hyperlipidemic effect (44, 58) induced by the absence of apoE in this mouse model. Similarly, even in the absence of lipolysis, catalytically inactive HL-S145G decreased the plasma levels of TC, TG, PL, CE, non-HDL-C, and apoB by up to 61% (p < 0.01). Thus, the lipolytic function of HL is not required for the reduction in apoB-Lp cholesterol in E-KO x HL-KO mice. In contrast, the effects of the lipolytic versus ligand-binding function of HL on HDL were quite distinct. HL-WT significantly reduced the plasma concentrations of HDL-C and apoA-I by 40 and 36% (p < 0.01), respectively, whereas the ligand-binding function of HL had no impact on plasma HDL-C or apoA-I levels in E-KO x HL-KO mice. The altered lipid profile of HL-WT and HL-S145G mice was not due to changes in lipoprotein lipase activity since it was reduced by ~23% in both groups of mice compared with E-KO x HL-KO mice; decreased lipolysis resulting from lower lipoprotein lipase activity would increase rather than decrease plasma TC, TG, and PL as well as apoB-Lp and HDL-C levels. These data are consistent with previous adenovirus and transgenic studies in E-KO mice (25, 26) and indicate that whereas the lipolytic function of HL significantly contributes to plasma HDL metabolism, the ligand-binding function of HL accounts for most of the reduction in the cholesterol-rich remnant lipoproteins that accumulate in E-KO x HL-KO mice.

Variability in HL activity contributes to changes not only in the plasma VLDL, IDL, remnant lipoprotein, and HDL levels (8, 9, 11–13, 15, 16, 19, 23, 24, 27, 28, 31), but also in LDL subclasses (7, 14, 41, 42). In humans, some of the pro-atherogenic effects of HL have been ascribed to changes in LDL particle density (7). Reduction in HL activity by pharmacological therapy is associated with an increase in LDL particle buoyancy, decreased levels of small, dense LDL, and reduced coronary atherosclerosis (7). In rabbits, HL overexpression leads to substantial reductions in medium and small VLDL, IDL, and HDL and to the accumulation of small, dense LDL (41, 42). Bergeron et al. (58) have also reported that HL deficiency in E-KO mice results in accumulation of heterogeneous, lipid-rich IDL and LDL as well as vesicular lipoproteins rich in both FC and PL. Thus, HL can change the composition of pro-atherogenic apoB-Lp and anti-atherogenic HDL, which may in turn alter their atherogenic potential. However, the separate effects of the lipolytic versus ligand-binding function of HL on VLDL, IDL, LDL, and HDL composition and particle size have not yet been investigated.

Our studies reveal that the lipolytic and ligand-binding functions of HL have differential effects on the particle size and lipid content of different plasma lipoproteins (Fig. 3 and Table I). Thus, the amount of TC, CE, TG, and PL in VLDL/IDL, LDL, and HDL isolated from E-KO x HL-WT mice was significantly decreased compared with E-KO x HL-KO mice. These data agree with previous reports indicating that HL deficiency leads to the accumulation of lipid-rich VLDL/IDL, LDL, and HDL in E-KO mice (58). Here, we have also demonstrated that even in the absence of HL lipolysis, expression of HL-S145G dramatically reduced the TC, CE, TG, and PL levels in VLDL/IDL. Furthermore, like HL-WT, HL-S145G virtually eliminated the 369- and 348-Å particles that accumulated in the VLDL/IDL fraction of E-KO x HL-KO mice. In contrast, LDL from E-KO x HL-S145G mice was more heterogeneous, larger, more lipid-rich, and more abundant than LDL from E-KO x HL-WT mice. Finally, unlike HL-WT, HL-S145G had virtually no effect on plasma HDL levels, lipid content, and particle size in E-KO x HL-KO mice.

The combined effects of HL-WT and HL-S145G on plasma lipoprotein particle lipid content, size, and levels (Figs. 2 and 3 and Table I) imply different roles for the lipolytic versus ligand-binding function of HL in the metabolism of VLDL/IDL, LDL, and HDL. First, the ligand-binding function of HL appears to be primarily responsible for facilitating the clearance of VLDL/IDL in E-KO x HL-WT and E-KO x HL-S145G mice. Second, the accumulation of polydisperse, lipid-rich LDL in E-KO x HL-S145G (but not E-KO x HL-WT) mice indicates that effective clearance of LDL requires the lipolytic function of HL. Finally, the lipolytic and not the ligand function of HL has a major effect on HDL metabolism in E-KO mice. To test these hypotheses and to gain further insight into the mechanisms by which the ligand-binding function of HL decreases the plasma levels of apoB-Lp, we examined the kinetics of radiolabeled VLDL/IDL and LDL containing only apoB-48 in E-KO x HL-KO, E-KO x HL-WT, and E-KO x HL-S145G mice. E-KO x HL-KO mice accumulate cholesterol-rich remnants that contain apoB-48 as their major apolipoprotein (44, 48, 58). Virtually no apoB-100-containing lipoproteins were present in the plasma of E-KO x HL-KO, E-KO x HL-WT, or E-KO x HL-S145G mice. Thus, injected autologous radiolabeled lipoproteins contained only apoB-48, with no apoE or apoB-100, leaving either HL-WT or HL-S145G to serve as the potential ligand for the two major receptors, the LDLR and LRP.

In the absence of apoE, both HL-WT and HL-S145G enhanced the FCR of 131I-apoB-48 VLDL/IDL by similar amounts (1.26- and 1.31-fold, respectively). These data provide an explanation for the similar reduction in the plasma levels of cholesterol, TG, and PL observed in Fig. 2 (A and B), as VLDL and IDL are the principal lipid-containing lipoproteins in the E-KO x HL-KO mice (44, 48, 58), and demonstrate that the ligand-binding and not the lipolytic function of HL is primarily responsible for enhancing the catabolism of VLDL/IDL in these mice. In contrast, HL-WT and HL-S145G differentially altered the catabolism of autologous LDL in the E-KO x HL-KO mouse model. Fully active HL-WT enhanced the FCR of mouse 125I-apoB-48 LDL by 3.33-fold, whereas inactive HL-S145G increased it by only 1.59-fold compared with E-KO x HL-KO mice. Thus, HL-WT was more effective in clearing autologous LDL than HL-S145G. These findings provide an explanation for the greater accumulation of LDL lipids and apoB in E-KO x HL-S145G versus E-KO x HL-WT mice (Table I). One possible explanation for the differences in mouse apoB-48 LDL catabolism between the two mouse groups could be variable expression of the LDLR. However, the hepatic expression of the LDLR was similar in E-KO x HL-WT and E-KO x HL-S145G mice (Fig. 4C, inset). Alternatively, the differences in mouse apoB-48 LDL catabolism may reflect the fact that LDL generated by the lipolytic action of HL on VLDL/IDL and remnant lipoproteins may be more efficiently cleared by cell-surface receptors, whereas the heterogeneous, lipid-rich LDL generated in E-KO x HL-S145G mice may be a less effective ligand for the lipoprotein receptors. Previous studies have in fact reported that changes in LDL particle lipid composition can alter the exposure of apolipoprotein epitopes and consequently the uptake of lipoproteins by cell-surface receptors (60–62).

The data presented in this study provide the first kinetic evidence demonstrating that HL enhances the plasma catabolism of apoB-Lp, a finding not observed in a previous kinetic study using recombinant adenovirus (25). A key difference between the two studies is that in this work, we studied mice with long-term, steady-state expression of HL-WT or HL-S145G with no endogenous mouse HL expression. In contrast, in the adenovirus experiments, transient expression of the human HL transgenes and the presence of the endogenous, fully active mouse HL may have confounded the effects of HL-WT and HL-S145G on VLDL, IDL, and LDL kinetics (25).

In vitro studies have provided evidence that HL can enhance cellular lipid/lipoprotein uptake by facilitating the interaction of apoB-Lp with LRP (15, 19, 20), the LDLR (17), SR-BI (22), and proteoglycans (16, 20). In addition, infusion of anti-HL and anti-LDLR antibodies in Swiss Webster mice (24) and expression of catalytically inactive HL in LDLR-KO mice (27) have provided evidence supporting a role of both the LDLR and LRP (24) or of LDLR-independent pathways (27) in HL-facilitated reduction of apoB-Lp in these two mouse models. This study provides direct in vivo evidence that LRP is a major pathway by which the ligand-binding function of HL facilitates the catabolism of apoB-Lp in E-KO x HL-KO mice. RAP inhibition of LRP function, measured by changes in hepatic uptake of {alpha}2-macroglobulin, delayed the plasma clearance of apoB-48 LDL (by 13%) and the hepatic uptake of 125I-radiolabeled apoB-48 LDL (by 36%) in HL-S145G-expressing mice. In contrast, neither HL-WT nor HL-S145G altered the catabolism of human apoB-100 LDL particles, which lack both apoE and apoB-48 and are presumably cleared primarily by the LDLR. The similar kinetics of human apoB-100 LDL in E-KO x HL-KO, E-KO x HL-WT, and E-KO x HL-S145G mice suggest that the LDLR may not be a major pathway by which HL-S145G facilitates apoB-Lp clearance. We caution, however, that this later kinetic study may not accurately reflect LDLR function since clearance of human apoB-100 LDL by the mouse LDLR has not been definitively demonstrated (63). These results demonstrate that the ligand-binding function of HL facilitates the cellular uptake of apoB-Lp via the LRP receptor pathway and are consistent with a recent study demonstrating that RAP blocks endocytosis of HL into rat liver hepatocytes (59).

Although HL-WT lowered the plasma concentrations of pro-atherogenic apoB-Lp by as much as 42%, it significantly worsened proximal aortic lesion development in both male and especially female E-KO x HL-WT mice on RCD. The ligand-binding function of HL does not appear to be responsible for the increased atherosclerosis observed in E-KO x HL-WT mice, as overexpression of the catalytically active form of HL is not pro-atherogenic. Thus, the increased atherosclerosis in E-KO x HL-WT versus E-KO x HL-KO mice can be ascribed to the lipolytic function of liver-expressed HL-WT. Hepatic expression of HL-WT was associated with decreased plasma HDL levels and the formation of smaller, lipid-poor LDL, both associated in humans with increased atherogenic risk (3–7).

In contrast to HL-WT, catalytically inactive HL-S145G significantly decreased aortic lesion formation (by 65–96%) in both male and female E-KO mice on RCD at 3, 5, and 7 months of age. The decreased atherosclerosis was not attributed to changes in plasma HDL levels. However, the ligand-binding function of HL markedly reduced apoB-containing cholesterol-rich remnants in E-KO x HL-KO mice and, in contrast to E-KO x HL-WT mice, led to the accumulation of heterogeneous, larger, and lipid-rich IDL and LDL. Our combined findings establish a protective role for the ligand-binding function of HL and indicate that in the absence of catalytic activity, HL does not lipolytically remodel apoB-Lp, but rather modulates atherosclerosis by enhancing removal of cholesterol-rich remnants via LRP. Since there is evidence that HL can complement and perhaps act synergistically with apoE to facilitate catabolism of apoB-Lp (41), it is possible that the beneficial effects of the ligand-binding function of HL are accentuated by the absence of apoE in this mouse model.

In summary, this study identifies LRP as a major receptor pathway by which the ligand-binding function of HL alters remnant lipoprotein uptake in E-KO x HL-KO mice and delineates the separate contributions of the lipolytic versus ligand-binding function of HL to plasma lipoprotein composition and metabolism, identifying physiologically relevant but divergent roles for the lipolytic versus ligand-binding function of HL in modulating the development of atherosclerosis in vivo.


   FOOTNOTES
 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed: Molecular Disease Branch, NHLBI, NIH, Bldg. 10, Rm. 7N115, 10 Center Dr., MSC 1666, Bethesda, MD 20892. Tel.: 301-496-5095; Fax: 301-402-0190; E-mail: silvia{at}mdb.nhlbi.nih.gov.

1 The abbreviations used are: HL, hepatic lipase; TG, triglyceride(s); PL, phospholipid(s); IDL, intermediate density lipoprotein(s); LDL, low density lipoprotein(s); HDL, high density lipoprotein(s); VLDL, very low density lipoprotein(s); HDL-C, high density lipoprotein cholesterol; LDLR, low density lipoprotein receptor(s); LRP, low density lipoprotein receptor-related protein; SR-BI, scavenger receptor class B, type I; RAP, receptor-associated protein; E-KO, apoE knockout; apoB-Lp, apoB-containing lipoprotein(s); KO, knockout; WT, wild-type; TC, total cholesterol; FC, free cholesterol; FPLC, fast protein liquid chromatography; FCR, fractional catabolic rate(s); CE, cholesterol ester; RCD, regular chow diet. Back


   ACKNOWLEDGMENTS
 
We thank Elizabeth Crawford for excellent secretarial and editorial assistance and Cindy McFarland for expert assistance in analysis of aortic lesions.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sanan, D. A., Fan, J., Bensadoun, A., and Taylor, J. M. (1997) J. Lipid Res. 38, 1002–1013[Abstract]
  2. Doolittle, M. H., Wong, H., Davis, R. C., and Schotz, M. C. (1987) J. Lipid Res. 28, 1326–1334[Abstract]
  3. Couture, P., Otvos, J. D., Cupples, L. A., Lahoz, C., Wilson, P. W., Schaefer, E. J., and Ordovas, J. M. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 815–822[Abstract/Free Full Text]
  4. Cohen, J. C., Vega, G. L., and Grundy, S. M. (1999) Curr. Opin. Lipidol. 10, 259–267[CrossRef][Medline] [Order article via Infotrieve]
  5. Campos, H., Dreon, D. M., and Krauss, R. M. (1995) J. Lipid Res. 36, 462–472[Abstract]
  6. Deeb, S. S., Zambon, A., Carr, M. C., Ayyobi, A. F., and Brunzell, J. D. (2003) J. Lipid Res. 44, 1279–1286[Abstract/Free Full Text]
  7. Zambon, A., Hokanson, J. E., Brown, B. G., and Brunzell, J. D. (1999) Circulation 99, 1959–1964[Abstract/Free Full Text]
  8. Shohet, R. V., Vega, G. L., Anwar, A., Cigarroa, J. E., Grundy, S. M., and Cohen, J. C. (1999) Arterioscler. Thromb. Vasc. Biol. 19, 1975–1978[Abstract/Free Full Text]
  9. Thuren, T. (2000) Curr. Opin. Lipidol. 11, 277–283[CrossRef][Medline] [Order article via Infotrieve]
  10. Perret, B., Mabile, L., Martinez, L., Terce, F., Barbaras, R., and Collet, X. (2002) J. Lipid Res. 43, 1163–1169[Abstract/Free Full Text]
  11. Connelly, P. W. (1999) Clin. Chim. Acta 286, 243–255[CrossRef][Medline] [Order article via Infotrieve]
  12. Olivecrona, G., and Olivecrona, T. (1995) Curr. Opin. Lipidol. 6, 291–305[Medline] [Order article via Infotrieve]
  13. Patsch, J. R., Prasad, S., Gotto, A. M., Jr., and Patsch, W. (1987) J. Clin. Investig. 80, 341–347A. M. J.[Medline] [Order article via Infotrieve]
  14. Zambon, A. A., Deeb, S. S., Pauletto, P. B., Crepaldi, G. A., and Brunzell, J. D. (2003) Curr. Opin. Lipidol. 14, 179–189S. S. D.[CrossRef][Medline] [Order article via Infotrieve]
  15. Krapp, A., Ahle, S., Kersting, S., Hua, Y., Kneser, K., Nielsen, M., Gliemann, J., and Beisiegel, U. (1996) J. Lipid Res. 37, 926–936[Abstract]
  16. Ji, Z.-S., Lauer, S. J., Fazio, S., Bensadoun, A., Taylor, J. M., and Mahley, R. W. (1994) J. Biol. Chem. 269, 13429–13436[Abstract/Free Full Text]
  17. Komaromy, M., Azhar, S., and Cooper, A. D. (1996) J. Biol. Chem. 271, 16906–16914[Abstract/Free Full Text]
  18. Diard, P., Malewiak, M.-I., Lagrange, D., and Griglio, S. (1994) Biochemical J. 299, 889–894[Medline] [Order article via Infotrieve]
  19. Choi, S. Y., Komaromy, M. C., Chen, J., Fong, L. G., and Cooper, A. D. (1994) J. Lipid Res. 35, 848–859[Abstract]
  20. Ji, Z.-S., Dichek, H. L., Miranda, R. D., and Mahley, R. W. (1997) J. Biol. Chem. 272, 31285–31292[Abstract/Free Full Text]
  21. Marques-Vidal, P., Azéma, C., Collet, X., Vieu, C., Chap, H., and Perret, B. (1994) J. Lipid Res. 35, 373–384[Abstract]
  22. Lambert, G., Chase, M. B., Dugi, K., Bensadoun, A., Brewer, H. B., Jr., and Santamarina-Fojo, S. (1999) J. Lipid Res. 40, 1294–1303[Abstract/Free Full Text]
  23. Shafi, S., Brady, S. E., Bensadoun, A., and Havel, R. J. (1994) J. Lipid Res. 35, 709–720[Abstract]
  24. de Faria, E., Fong, L. G., Komaromy, M., and Cooper, A. D. (1996) J. Lipid Res. 37, 197–209[Abstract]
  25. Amar, M. J. A., Dugi, K. A., Haudenschild, C. C., Shamburek, R. D., Foeger, B., Chase, M., Bensadoun, A., Hoyt, R. F., Jr., Brewer, H. B., Jr., and Santamarina-Fojo, S. (1998) J. Lipid Res. 39, 2436–2442[Abstract/Free Full Text]
  26. Dichek, H. L., Brecht, W., Fan, J., Ji, Z.-S., McCormick, S. P. A., Akeefe, H., Conzo, L., Sanan, D. A., Weisgraber, K. H., Young, S. G., Taylor, J. M., and Mahley, R. W. (1998) J. Biol. Chem. 273, 1896–1903[Abstract/Free Full Text]
  27. Dichek, H. L., Johnson, S. M., Akeefe, H., Lo, G. T., Sage, E., Yap, C. E., and Mahley, R. W. (2001) J. Lipid Res. 42, 201–210[Abstract/Free Full Text]
  28. Dugi, K. A., Amar, M. J. A., Haudenschild, C. C., Shamburek, R. D., Bensadoun, A., Hoyt, R. F., Jr., Fruchart-Najib, J., Madj, Z., Brewer, H. B., Jr., and Santamarina-Fojo, S. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 793–800[Abstract/Free Full Text]
  29. Dichek, H. L., Qian, K., and Agrawal, N. (2004) J. Lipid Res. 45, 551–560[Abstract/Free Full Text]
  30. Zambon, A., Deeb, S. S., Bensadoun, A., Foster, K. E., and Brunzell, J. D. (2000) J. Lipid Res. 41, 2094–2099[Abstract/Free Full Text]
  31. Santamarina-Fojo, S., Haudenschild, C., and Amar, M. J. A. (1998) Curr. Opin. Lipidol. 9, 211–219[CrossRef][Medline] [Order article via Infotrieve]
  32. Jansen, H., Verhoeven, A. J. M., and Sijbrands, E. J. G. (2002) J. Lipid Res. 43, 1352–1362[Abstract/Free Full Text]
  33. Beisiegel, U. (1996) Atherosclerosis 124, 1–8[CrossRef][Medline] [Order article via Infotrieve]
  34. Dugi, K. A., Brandauer, K., Schmidt, N., Nau, B., Schneider, J. G., Mentz, S., Keiper, T., Schaefer, J. R., Meissner, C., Kather, H., Bahner, M. L., Fiehn, W., and Kreuzer, J. (2001) Circulation 104, 3057–3062[Abstract/Free Full Text]
  35. Connelly, P. W., and Hegele, R. A. (1998) Crit. Rev. Clin. Lab. Sci. 35, 547–572[CrossRef][Medline] [Order article via Infotrieve]
  36. Katzel, L. I., Coon, P. J., Busby, M. J., Gottlieb, S. O., Krauss, R. M., and Goldberg, A. P. (1992) Arterioscler. Thromb. 12, 814–823[Abstract/Free Full Text]
  37. Zambon, A., Deeb, S. S., Brown, B. G., Hokanson, J. E., and Brunzell, J. D. (2001) Circulation 103, 792–798[Abstract/Free Full Text]
  38. Lamarche, B., Tchernoff, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., and Despres, J. P. (1997) Circulation 95, 69–75[Abstract/Free Full Text]
  39. Fan, J., Wang, J., Bensadoun, A., Lauer, S. J., Dang, Q., Mahley, R. W., and Taylor, J. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8724–8728[Abstract/Free Full Text]
  40. Busch, S. J., Barnhart, R. L., Martin, G. A., Fitzgerald, M. C., Yates, M. T., Mao, S. J., Thomas, C. E., and Jackson, R. L. (1994) J. Biol. Chem. 269, 16376–16382[Abstract/Free Full Text]
  41. Barbagallo, C. M., Fan, J., Blanche, P. J., Rizzo, M., Taylor, J. M., and Krauss, R. M. (1999) Arterioscler. Thromb. Vasc. Biol. 19, 625–632[Abstract/Free Full Text]
  42. Rizzo, M., Taylor, J. M., Barbagallo, C. M., Berneis, K., Blanche, P. J., and Krauss, R. M. (2004) Arterioscler. Thromb. Vasc. Biol. 24, 141–146[Abstract/Free Full Text]
  43. Qiu, S.-Q., Bergeron, N., Kotite, L., Krauss, R. M., Bensadoun, A., and Havel, R. J. (1998) J. Lipid Res. 39, 1661–1668[Abstract/Free Full Text]
  44. Mezdour, H., Jones, R., Dengremont, C., Castro, G., and Maeda, N. (1997) J. Biol. Chem. 272, 13570–13575[Abstract/Free Full Text]
  45. Nong, Z., González-Navarro, H., Amar, M. J. A., Freeman, L., Knapper, C., Neufeld, E. B., Paigen, B. J., Hoyt, R. F., Fruchart-Najib, J., and Santamarina-Fojo, S. (2003) J. Clin. Investig. 112, 367–378[CrossRef][Medline] [Order article via Infotrieve]
  46. González-Navarro, H., Nong, Z., Freeman, L., Bensadoun, A., Peterson, K., and Santamarina-Fojo, S. (2002) J. Lipid Res. 43, 671–675[Abstract/Free Full Text]
  47. Homanics, G. E., De Silva, H. V., Osada, J., Zhang, S. H., Wong, H., Borensztajn, J., and Maeda, N. (1995) J. Biol. Chem. 270, 2974–2980[Abstract/Free Full Text]
  48. Zhang, S. H., Reddick, R. L., Piedrahita, J. A., and Maeda, N. (1992) Science 258, 468–471[Abstract/Free Full Text]
  49. Cisar, L. A., and Bensadoun, A. (1985) J. Lipid Res. 26, 380–386[Abstract]
  50. Cheng, C.-F., Bensadoun, A., Bersot, T., Hsu, J. S., and Melford, K. H. (1985) J. Biol. Chem. 260, 10720–10727[Abstract/Free Full Text]
  51. Iverius, P.-H., and Brunzell, J. D. (1985) Am. J. Physiol. 249, E107–E114[Medline] [Order article via Infotrieve]
  52. Nichols, A. V., Krauss, R. M., and Musliner, T. A. (1986) Methods Enzymol. 128, 417–431[Medline] [Order article via Infotrieve]
  53. McFarlane, A. S. (1958) Nature 182, 53–57[Medline] [Order article via Infotrieve]
  54. Greif, P., Wastney, M., Linares, O., and Boston, R. (1998) Adv. Exp. Med. Biol. 445, 3–20[Medline] [Order article via Infotrieve]
  55. Herz, J., Qiu, S.-Q., Oesterle, A., De Silva, H. V., Shafi, S., and Havel, R. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4611–4615[Abstract/Free Full Text]
  56. Van Leuven, F., Cassiman, J.-J., and Van Den Berghe, H. (1981) J. Biol. Chem. 256, 9016–9022[Free Full Text]
  57. Paigen, B., Holmes, P. A., Mitchell, D., and Albee, D. (1987) Atherosclerosis 64, 215–221[CrossRef][Medline] [Order article via Infotrieve]
  58. Bergeron, N., Kotite, L., Vergés, M., Blanche, P., Hamilton, R. L., Krauss, R. M., Bensadoun, A., and Havel, R. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 15647–15652[Abstract/Free Full Text]
  59. Vergés, M., Bensadoun, A., Herz, J., Belcher, J. D., and Havel, R. J. (2004) J. Biol. Chem. 279, 9030–9036[Abstract/Free Full Text]
  60. Aviram, M., Lund-Katz, S., Phillips, M. C., and Chait, A. (1988) J. Biol. Chem. 263, 16842–16848[Abstract/Free Full Text]
  61. Flood, C., Gustafsson, M., Pitas, R. E., Arnaboldi, L., Walzem, R. L., and Boren, J. (2004) Arterioscler. Thromb. Vasc. Biol. 24, 564–570[Abstract/Free Full Text]
  62. Marcel, Y. L., Hogue, M., Weech, P. K., Davignon, J., and Milne, R. W. (1988) Arteriosclerosis 8, 832–844[Abstract/Free Full Text]
  63. Dietschy, J. M., Turley, S. D., and Spady, D. K. (1993) J. Lipid Res. 34, 1637–1659[Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
M. Gomez, S. M. Sanz-Gonzalez, Y. N. A. Nabah, A. Lamana, F. Sanchez-Madrid, and V. Andres
Atherosclerosis development in apolipoprotein E-null mice deficient for CD69
Cardiovasc Res, January 1, 2009; 81(1): 197 - 205.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Isaacs, Y. S. Aulchenko, A. Hofman, E. J. G. Sijbrands, F. A. Sayed-Tabatabaei, O. H. Klungel, A.-H. Maitland-van der Zee, B. H. Ch. Stricker, B. A. Oostra, J. C. M. Witteman, et al.
Epistatic Effect of Cholesteryl Ester Transfer Protein and Hepatic Lipase on Serum High-Density Lipoprotein Cholesterol Levels
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2680 - 2687.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
L. Freeman, M. J. A. Amar, R. Shamburek, B. Paigen, H. B. Brewer Jr., S. Santamarina-Fojo, and H. Gonzalez-Navarro
Lipolytic and ligand-binding functions of hepatic lipase protect against atherosclerosis in LDL receptor-deficient mice
J. Lipid Res., January 1, 2007; 48(1): 104 - 113.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. Lambert, A.-L. Jarnoux, T. Pineau, O. Pape, M. Chetiveaux, C. Laboisse, M. Krempf, and P. Costet
Fasting Induces Hyperlipidemia in Mice Overexpressing Proprotein Convertase Subtilisin Kexin Type 9: Lack of Modulation of Very-Low-Density Lipoprotein Hepatic Output by the Low-Density Lipoprotein Receptor
Endocrinology, October 1, 2006; 147(10): 4985 - 4995.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. L. Karackattu, B. Trigatti, and M. Krieger
Hepatic Lipase Deficiency Delays Atherosclerosis, Myocardial Infarction, and Cardiac Dysfunction and Extends Lifespan in SR-BI/Apolipoprotein E Double Knockout Mice
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 548 - 554.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/44/45312    most recent
M406495200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by González-Navarro, H.
Right arrow Articles by Santamarina-Fojo, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by González-Navarro, H.
Right arrow Articles by Santamarina-Fojo, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement